APA (7th ed.) Citation

Fukushima, Y., Kimura, G., Akatsuka, J., Honda, Y., Nakaoka, Y., Hayashi, H., & Kumita, S. (2026). Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223. EJNMMI Reports, 10(1), 1. https://doi.org/10.1186/s41824-026-00309-4

Chicago Style (17th ed.) Citation

Fukushima, Yoshimitsu, Go Kimura, Jun Akatsuka, Yoshimitsu Honda, Yujiro Nakaoka, Hiromitsu Hayashi, and Shinichiro Kumita. "Quantitative Bone SPECT/CT-derived Tumor Burden as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with Ra-223." EJNMMI Reports 10, no. 1 (2026): 1. https://doi.org/10.1186/s41824-026-00309-4.

MLA (9th ed.) Citation

Fukushima, Yoshimitsu, et al. "Quantitative Bone SPECT/CT-derived Tumor Burden as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with Ra-223." EJNMMI Reports, vol. 10, no. 1, 2026, p. 1, https://doi.org/10.1186/s41824-026-00309-4.